Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study

de Marinis, F.;Kim, T. M.;Bonanno, L.;Cheng, S.;Kim, S. -W.;Tiseo, M.;Chu, Q.;Proto, C.;Sacher, A.;Luo, Y. -H.;Novello, S.;Hao, D.;Baik, C.;Bazhenova, L.;Lee, J. S.;Cho, B. C.;Cadranel, J.;Diep, T. B.;Metro, G.;Narayanan, P.;Yoneshima, Y.;de Castro Carpeño, J.;Baldotto, C.;Nyhus, C.;Yang, J. C. -H.;Sequist, L. V.;Levy, B.;Hartmaier, R.;Igwegbe, I.;Poole, L.;Xu, W.;Ahn, M. -J.

2025